Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,959 | $9,892 | $10,446 | $11,555 |
| G&A Expenses | $4,500 | $2,621 | $3,146 | $2,781 |
| SG&A Expenses | $4,500 | $2,621 | $3,146 | $2,781 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,459 | $12,513 | $13,592 | $14,336 |
| Operating Income | -$14,459 | -$12,513 | -$13,592 | -$14,336 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,216 | $1,317 | $1,481 | $2,592 |
| Pre-Tax Income | -$13,370 | -$11,292 | -$12,523 | -$11,744 |
| Tax Expense | -$127 | -$96 | -$412 | -$124 |
| Net Income | -$13,243 | -$11,196 | -$12,111 | -$11,620 |
| % Margin | – | – | – | – |
| EPS | -0.16 | -0.13 | -0.14 | -0.14 |
| % Growth | -23.1% | 7.1% | 0% | – |
| EPS Diluted | -0.16 | -0.13 | -0.14 | -0.14 |
| Weighted Avg Shares Out | 85,381 | 85,074 | 84,806 | 84,002 |
| Weighted Avg Shares Out Dil | 85,381 | 85,074 | 84,806 | 84,002 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,075 | $1,210 | $1,394 | $1,759 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $12,417 | $1,057 | -$22,748 |
| EBITDA | -$13,370 | $1,125 | -$11,466 | -$34,019 |
| % Margin | – | – | – | – |